The Skeptic's critique, while raising legitimate concerns about delivery and heterogeneity, fundamentally mischaracterizes the proposed therapeutic strategy by treating it as a monolithic intervention rather than a precision medicine framework. The eRNA approach is explicitly designed for the genetically defined subset of ALS-FTD patients where TDP-43 mutations create identifiable pathological RNA interactomes—the approximately 5% of ALS cases with *TARDBP* mutations and the significant fraction
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.60
Evidence
0.55
Novelty
0.60
Feasibility
0.00
Impact
0.00
Druggability
0.00
Safety
0.00
Competition
0.00
Data
0.00
Reproducible
0.00
KG Connect
0.50
Score Breakdown
Dimension
Resolving Mechanistic Heteroge
Mechanistic
0.600
Evidence
0.550
Novelty
0.600
Feasibility
0.000
Impact
0.000
Druggability
0.000
Safety
0.000
Competition
0.000
Data
0.000
Reproducible
0.000
KG Connect
0.500
Evidence
Resolving Mechanistic Heterogeneity Through Precision Medici